Sonoma Biotherapeutics is a privately held company leading the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/06/20 | $40,000,000 | Series A |
ARCH Venture Partners Lyell Immunopharma Milky Way Ventures | undisclosed |
| 09/30/20 | $30,000,000 | Series A |
Alexandria Venture Investments ARCH Venture Partners JDRF T1D Fund LifeForce Capital Lilly Asia Ventures Lyell Immunopharma Octagon Capital | undisclosed |
| 08/04/21 | $265,000,000 | Series B |
Ally Bridge Group ArrowMark Partners Avidity Partners Casdin Capital Deep Track Capital Fidelity Management & Research Company Frazier Healthcare Partners GV Janus Henderson Investors Mirae Asset Venture Investment NS Investment Osage University Partners | undisclosed |
